SCHEMBL14734743

SCHEMBL14734743

COc1ccc(-c2ccc3c(c2)CNC3=O)c(OCC(C)(C)OC(=O)CC2CCCC2)c1OC

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.36
HPGD P15428 4/20 0.36
GPR119 Q8TDV5 1/20 0.36
POLQ O75417 1/20 0.34
PRF1 P14222 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
LMNA P02545 1/20 0.33
DAPK3 O43293 1/20 0.33
NTRK1 P04629 1/20 0.33
PIM1 P11309 1/20 0.33
FLT3 P36888 1/20 0.33
ROCK1 Q13464 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
PRKCI P41743 1/20 0.32
LRRK2 Q5S007 1/20 0.32
TDP2 O95551 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14737704 0.88 GSK3B (0.39) GSK3BHPGDGPR119POLQPRF1
SCHEMBL14734754 0.88 GSK3B (0.38) GSK3BGPR119POLQPRF1MAPKAPK2
SCHEMBL14738485 0.87 GSK3B (0.39) GSK3BHPGDGPR119POLQPRF1
SCHEMBL2584838 0.87 POLQ (0.37) GSK3BGPR119POLQPRF1MAPKAPK2
SCHEMBL2584358 0.87 POLQ (0.39) GSK3BGPR119POLQPRF1MAPKAPK2
SCHEMBL14737338 0.86 GSK3B (0.39) GSK3BHPGDGPR119POLQPRF1
SCHEMBL14736892 0.86 HSD17B1 (0.40) HPGDGPR119LMNA
SCHEMBL14736661 0.86 GSK3B (0.43) GSK3BGPR119POLQPRF1MAPKAPK2
SCHEMBL14734800 0.86 PRKCI (0.36) GSK3BPOLQPRF1MAPKAPK2DAPK3
SCHEMBL14734803 0.85 GSK3B (0.36) GSK3BGPR119POLQPRF1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A GSK3B 350/4885HPGD 1088/4885GPR119 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.